|
注册号: Registration number: |
ChiCTR2400092456 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-18 08:59:11 |
|
注册时间: Date of Registration: |
2024-11-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
骨科智能导航系统在新鲜股骨颈骨折治疗中的前瞻性、多中心、随机对照临床研究 |
|
Public title: |
Prospective, multicenter, randomized controlled clinical study of orthopedic intelligent navigation system in the treatment of fresh femoral neck fractures |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
骨科智能导航系统在新鲜股骨颈骨折治疗中的前瞻性、多中心、随机对照临床研究 |
|
Scientific title: |
Prospective, multicenter, randomized controlled clinical study of orthopedic intelligent navigation system in the treatment of fresh femoral neck fractures |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张巍 |
研究负责人: |
张巍 |
|
Applicant: |
Wei Zhang |
Study leader: |
Wei Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 186 1240 9252 |
研究负责人电话:
Study leader's |
+86 186 1240 9252 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
bszw@hotmail.com |
研究负责人电子邮件: Study leader's E-mail: |
bszw@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区阜成路51号 |
研究负责人通讯地址: |
北京市海淀区阜成路51号 |
|
Applicant address: |
No. 51 Fucheng Road, Beijing, China |
Study leader's address: |
No. 51 Fucheng Road, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军总医院 |
||
|
Applicant's institution: |
PLA General Hospital |
||
|
研究负责人所在单位: |
中国人民解放军总医院 |
||
|
Affiliation of the Leader: |
PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审第S2024-341-01号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Of Chinese PLA General Hosptial |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-29 00:00:00 | ||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Jiang Cao |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
No. 28 Fuxing Road, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6693 7166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军总医院第一医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
first Medical Center of PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 28 Fuxing Road, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China |
||||||||||||||||||||||
|
研究疾病: |
股骨颈骨折 |
||||||||||||||||||||||
|
Target disease: |
fracture of neck of femur |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
验证骨科手术导航系统在治疗新鲜股骨颈骨折的安全性和有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To verify the safety and effectiveness of orthopaedic surgical navigation system in the treatment of fresh femoral neck fractures. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)受试者入选前参加过其他药物、生物制剂或医疗器械临床研究未达到主要研究终点时限者; (2)已知患者对一种或多种植入的材料有过敏史; (3)经研究者判定,体质虚弱或因全身其他疾病不能耐受手术者; (4)经研究者判定髋关节或身体其他部位存在活动性感染病灶; (5)确诊为代谢性骨病、放射性骨病等; (6)严重的髋关节挛缩畸形或严重肌力减退长时间融合于功能位且无痛; (7)患有炎症性关节炎,如类风湿性关节炎,系统性红斑狼疮性关节炎,强直性脊柱炎等; (8)患者精神上无能力或者不能理解参与研究的要求,难以配合者; (9)研究者判断不适合入选的其他情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Participants who had participated in clinical studies of other drugs, biologics or medical devices before enrollment and did not reach the primary study endpoint time limit; (2) The patient is known to have a history of allergy to one or more implanted materials; (3) Patients determined by researchers to be physically weak or unable to tolerate surgery due to other systemic diseases; (4) Active infection of the hip joint or other parts of the body is determined by the investigator; (5) Diagnosed as metabolic bone disease, radiation bone disease, etc.; (6) Severe hip contracture deformity or severe muscle loss fused to the functional position for a long time without pain; (7) have inflammatory arthritis, such as rheumatoid arthritis, systemic lupus erythematosus arthritis, ankylosing spondylitis, etc.; (8) The patient is mentally incapable or unable to understand the requirements of participating in the study, and it is difficult to cooperate; (9) Other conditions deemed unsuitable for inclusion by the investigator. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-11-18 00:00:00至 To 2026-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-11-18 00:00:00 至 To 2026-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
用数字随机法进行随机分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The numerical randomization method is used for random grouping |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
NA |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No sharing IPD |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form and Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |